SOPHiA GENETICS

📣 Read our latest Customer Spotlight! We would like to warmly thank Manuela Badiali, Rita Congiu, and Stefania Murru from the Laboratory of Genetics and Genomics, Microcitemico Pediatric Hospital – A. Cao, Cagliari, for sharing their experience of how SOPHiA DDM™ RNAtarget Technology has helped them optimize their variant analysis workflow. Ospedale Oncologico Arnas G. Brotzu Read the full spotlight here: https://loom.ly/s8ImiJM #RNASeq #variantanalysis #NGS #datadrivenmedicine

🚀 October has been an action-packed month at SOPHiA GENETICS! With Dr. Jurgi Camblong’s new Research Spotlight already making waves, inspiring customer stories, science hub insights, and global breast cancer awareness efforts, we’re showing in our social media newsletter how we're pushing the boundaries of data-driven medicine. 💌  Plus, there’s an exciting invitation waiting for you in this month’s social media newsletter — don’t miss out! Subscribe and read the latest edition here. #DataDrivenMedicine #LinkedInNewsletter #MonthlyNewsletter #CorporateNews

I’m excited to share the second edition of Research Spotlight, highlighting findings from a multicenter trial published in The Lancet Haematology. The trial used SOPHiA DDM™ Dx Myeloid Solution, one of our CE-IVD applications.    The study focused on acute myeloid leukemia (#AML) patients aged 60-74, where allogenic hematopoietic stem-cell transplantation (HSCT) is the only curative option. However, accessing HSCT is often a challenge for older patients who less frequently reach remission, required for transplantation eligibility.     The recent trial of an Italian cohort tested whether first-line treatment with ventoclax plus decitabine could help achieve remission.    Throughout the trial, our SOPHiA DDM™ Dx Myeloid Solution was used to assess the biological characteristics of the patients’ AML and monitor residual disease. The results?    •  Ventoclax plus decitabine treatment achieved remission in 69% (64/93) of patients  •  57% (53/93) of patients ultimately underwent HSCT  •  Of the genes tested by NGS, only mutation of CSF3R showed any correlation with response to ventoclax plus decitabine, in this case a higher rate of non-response    These findings highlight ventoclax plus decitabine treatment as an effective bridge to HSCT for older patients.    You can read the publication here: https://lnkd.in/e7pKb2FH #ResearchSpotlight

🚀 At SOPHiA GENETICS, we’re shaping the future by investing in our emerging leaders! This October, we launched our new Emerging Leader Program with two highly interactive sessions that brought together diverse groups from different departments. The goal? To equip both experienced and aspiring leaders with hands-on tools to elevate their teams and lead with impact. From setting effective goals to creating a culture of trust and feedback, each participant left with concrete skills to apply right away. It was an incredible experience filled with lively exchanges and peer-to-peer learning, creating a true environment of growth and support. 🌱 We’re equally excited to announce upcoming remote sessions to make this opportunity accessible to our home-based emerging leaders. #LeadershipDevelopment #EmergingLeaders #TeamGrowth #LeadershipJourney Lucas Marques da Cunha, Antonio Ridi, Yvan Wenger, Jose Maria Rincon Garriz, Dragos Constantin, Mark Laver, Martin Vivies, Sofia Ridray, Erin Gunduz, M.Eng, PMP®, CLSSGB, Michella Ghassibe, Antonio Ridi, Anthony Sader, Christina Gkintzou, Ingrid Di Lorenzo, Floriane Consales Barras, Fanny Lanfranchi, Bita Khalili, Julie Romain, Simona Sevdina, Adrian Janiszewski, Nicola Dynes.

💡The SOPHiA DDM™ Platform complemented by Alamut™ Visual Plus offers streamlined Exome analysis workflows (from FASTQ file to variant report) for the efficient identification of genomic variants associated with rare and inherited diseases. ❗In a single workflow, the SOPHiA DDM™ Platform analyzes variants in mtDNA alongside SNVs, Indels, and CNVs in both coding and disease-relevant non-coding regions of nuclear DNA (nDNA). 🧬Alamut™ Visual Plus connects you to curated databases and prediction tools while providing enhanced variant visualization, so you can quickly confirm and report causative variants for complex conditions. ➡️ Learn more or get a demo SOPHiA DDM™ and Alamut™ Visual Plus today: https://lnkd.in/dj_F6_-k

🇪🇸 Next stop... Palma de Mallorca! Join SOPHiA GENETICS and our trusted regional partner Diagnostica Longwood at the 66th edition of the national Sociedad Española de Hematología y Hemoterapia (SEHH)! 💡Come and meet our team of experts at #Hemato2024 for the next two days and discover more about our hemato-oncology applications, our latest developments, and the New Generation SOPHiA DDM™ Platform! We can't wait to meet you! 🌍 #DataDrivenMedicine #Hematology #HematoOncology #PrecisionMedicine #SEHH2024

🧬 Why should you consider a matched tumor-normal approach for your genomic profiling? One major limitation of tumor-only sequencing is its inability to accurately distinguish somatic mutations driving tumorigenesis from germline and clonal hematopoietic variants. Having a complete picture of a tumor’s genomic makeup is crucial for accurate assessment and informed decision-making. In our latest blog, we discuss the benefits of matched tumor-normal sequencing, including its ability to: ➡️ Retain true somatic variants calls. ➡️ Reduce noise caused by sample variability and sequencing artifacts. ➡️ Remove false positives originating from clonal hematopoietic of indeterminate potential (CHIP) variants. ➡️ Streamline germline variant analysis. Read here to learn more: https://loom.ly/WV8JOF0 #NGS #Oncology #CGP #LiquidBiopsy #SolidTumors

🆕 WEBINAR ALERT! Measurable Residual Disease (MRD) has become a crucial biomarker in understanding and tracking tumor evolution, assessing treatment effectiveness, and predicting relapse in AML. Among the cutting-edge technologies for detecting MRD, next-generation sequencing (NGS) offers unparalleled sensitivity and specificity. 💡 Join us for an insightful webinar featuring Silvia Salmoiraghi, biologist at ASST Papa Giovanni XXIII Hospital in Bergamo, Italy, as she explores the performance of the NEW SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution. Discover how this innovative solution enhances MRD detection, paving the way for more accurate prognosis while offering better insights for treatment strategies in AML. Dr. Salmoiraghi will cover: ✅ The process of evaluating and implementing this new capture-based NGS application. ✅ The accurate detection of MRD while assessing multiple biomarkers. ✅ The advantages of adopting an NGS-based application compared to other technologies. 💻 Register today: https://loom.ly/WrdzYic #MRD #NGS #SOPHIADDM #Hematology

Exciting news! Manuela da Silva Valente, our Chief People Officer, is featured in Built In Boston, showcasing how SOPHiA GENETICS is transforming global healthcare through a culture of growth, collaboration, and our guiding mantra "We Care." At SOPHiA GENETICS, we are at the forefront of data-driven medicine and also empowering our people to thrive, take ownership, and make a real impact. Manuela’s leadership drives our mission forward, creating a space where passion meets purpose. Curious how we’re shaping the future of healthcare through data-driven mission and #culture? 🔗 Check out the full article: https://loom.ly/GBbyFWE #Media #WeCare #Leadership #DataDrivenMedicine #HealthcareInnovation

📣 #Media and #investors, mark your calendars! SOPHiA GENETICS (Nasdaq: SOPH) will release its financial results for the third quarter of 2024 on November 5, 2024. Join us for the earnings call at 8:00 a.m. EDT / 2:00 p.m. CET, where we'll present our financial performance and business outlook. Catch the live webcast on our Investor Relations website: https://loom.ly/6qJFj2o. A replay will also be available afterward. #EarningsCall #InvestorRelations #MediaAlert #FinancialResults